干扰素β治疗多发性硬化症对磁共振成像（MRI）增强病灶的影响因病灶大小和病理情况而异。

Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology.

作者信息

Filippi M, Rovaris M, Capra R, Gasperini C, Prandini F, Martinelli V, Horsfield M A, Bastianello S, Sormani M P, Pozzilli C, Comi G

机构信息

Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute Ospedale San Raffaele, University of Milan, Milan, Italy.

出版信息

J Neurol Neurosurg Psychiatry. 1999 Sep;67(3):386-9. doi: 10.1136/jnnp.67.3.386.

DOI:10.1136/jnnp.67.3.386

PMID:10449565

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1736516/

Abstract

OBJECTIVE

The ability of recombinant human interferon beta-1a (rh-IFN beta-1a) to suppress multiple sclerosis activity, evaluated from MRI, was assessed across a range of lesions enhancing at different gadolinium-DTPA (Gd) doses and with different sizes.

METHODS

Every 4 weeks, standard dose (Sd; 0.1 mmol/kg Gd) and triple dose (Td; 0.3 mmol/kgGd) MRI were obtained from 18 patients with relapsing-remitting multiple sclerosis for 3 months before and 4 months after starting treatment with 44 microgram rh-IFN beta-1a subcutaneously, once a week.

RESULTS

The total numbers of enhancing lesions were 145 and 126 on Sd scans and 278 and 192 on the Td scans obtained before and after treatment. The introduction of treatment decreased, on average, the rate of appearance of new enhancing lesions seen on Sd and Td scans by 37% (p<0.001). Treatment effects on new enhancing lesions seen on Td scans was, on average, 28% higher than on those seen on Sd scans. The distribution of lesion sizes on Td scans changed significantly during the treatment period (p=0.05), due to a marked decrease in the number of small lesions.

CONCLUSIONS

The effect of 44 microgram rh-IFN beta-1a in reducing multiple sclerosis disease activity, as monitored by Gd enhanced MRI, is not homogeneous, but graduated according to the pathological characteristics and size of the lesions.

摘要

目的

通过磁共振成像（MRI）评估重组人干扰素β-1a（rh-IFNβ-1a）抑制多发性硬化活动的能力，该评估针对一系列在不同钆-二乙三胺五乙酸（Gd）剂量及不同大小下强化的病灶。

方法

18例复发缓解型多发性硬化患者在皮下注射44微克rh-IFNβ-1a每周一次治疗前3个月及治疗后4个月期间，每4周进行一次标准剂量（Sd；0.1 mmol/kg Gd）和三倍剂量（Td；0.3 mmol/kg Gd）的MRI检查。

结果

治疗前及治疗后Sd扫描上强化病灶总数分别为145个和126个，Td扫描上分别为278个和192个。治疗的引入使Sd和Td扫描上可见的新强化病灶出现率平均降低了37%（p<0.001）。治疗对Td扫描上可见的新强化病灶的效果平均比对Sd扫描上的高28%。治疗期间Td扫描上病灶大小的分布发生了显著变化（p=0.05），原因是小病灶数量明显减少。